Next Article in Journal
Histologic Classification of Non-Small-Cell Lung Cancer over Time: Reducing the Rates of Not-Otherwise-Specified
Previous Article in Journal
Relationship between Progression-Free Survival and Overall Survival in Chronic Lymphocytic Leukemia: A Literature-Based Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 3
10.3747/co.22.2296
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Kinase Inhibitors or Docetaxel in Second-Line Treatment of EGFR Wild-Type Non-small-Cell Lung Cancer: A Retrospective Real-World Practice Review at a Single Tertiary Care Centre

by
K. Ma
1,*,
V. Cohen
2,
G. Kasymjanova
2,
D. Small
2,
K. Novac
3,
J. Peterson
3,
A. Levit
3 and
J. Agulnik
2
1
Division of Hematology Oncology, McGill University, Montreal, PQ, Canada
2
Peter Brojde Lung Cancer Centre, Jewish General Hospital, Montreal, PQ H3T 1E2, Canada
3
McGill University, Montreal, PQ, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(3), 157-163; https://doi.org/10.3747/co.22.2296
Submission received: 4 March 2015 / Revised: 3 April 2015 / Accepted: 2 May 2015 / Published: 1 June 2015

Abstract

Background Treatment for advanced non-small-cell lung cancer (NSCLC), especially in patients with wild-type EGFR, remains limited. Recently, erlotinib, a tyrosine kinase inhibitor (TKI) targeting EGFR mutation, was approved as second-line treatment in EGFR wild-type NSCLC. Despite evidence of better overall survival (OS) with chemotherapy than with TKI in second-line treatment, data on the use of TKI in the real-life clinical setting remain limited. The present practice review of TKI use for second- and third-line treatment in EGFR wild-type NSCLC also compares clinical outcomes for TKI and single-agent docetaxel as second-line treatment. Methods Our retrospective cohort study included patients with EGFR wild-type NSCLC treated at the Jewish General Hospital (Montreal, QC) between 2003 and 2013. Patients received a TKI (erlotinib or gefitinib) in the second and third line or docetaxel in the second line. For each group, we determined OS, disease control rate, progression-free survival (PFS), and event-free survival (EFS). Results The TKI group included 145 patients, with 92 receiving second-line treatment. In the control group, 53 patients received docetaxel as second-line therapy. In the TKI group, OS was 6.0 months; PFS, 2.7 months; and EFS, 3.0 months. Comparing second-line treatments, OS was 5.3 and 5.0 months respectively (p = 0.88), PFS was 2.5 and 1.8 months respectively (p = 0.041), and EFS was 3.0 and 1.7 months respectively (p = 0.009). Conclusions In our study cohort, second-line therapy for EGFR wild-type NSCLC with TKI (compared with docetaxel) was associated with statistically better PFS and EFS and noninferior OS. Those findings raise the question of whether EFS should also be considered when choosing second-line treatment in this patient population.
Keywords: Non-small-cell lung cancer; advanced disease; second-line treatment; tyrosine kinase inhibitors; docetaxel Non-small-cell lung cancer; advanced disease; second-line treatment; tyrosine kinase inhibitors; docetaxel

Share and Cite

MDPI and ACS Style

Ma, K.; Cohen, V.; Kasymjanova, G.; Small, D.; Novac, K.; Peterson, J.; Levit, A.; Agulnik, J. Kinase Inhibitors or Docetaxel in Second-Line Treatment of EGFR Wild-Type Non-small-Cell Lung Cancer: A Retrospective Real-World Practice Review at a Single Tertiary Care Centre. Curr. Oncol. 2015, 22, 157-163. https://doi.org/10.3747/co.22.2296

AMA Style

Ma K, Cohen V, Kasymjanova G, Small D, Novac K, Peterson J, Levit A, Agulnik J. Kinase Inhibitors or Docetaxel in Second-Line Treatment of EGFR Wild-Type Non-small-Cell Lung Cancer: A Retrospective Real-World Practice Review at a Single Tertiary Care Centre. Current Oncology. 2015; 22(3):157-163. https://doi.org/10.3747/co.22.2296

Chicago/Turabian Style

Ma, K., V. Cohen, G. Kasymjanova, D. Small, K. Novac, J. Peterson, A. Levit, and J. Agulnik. 2015. "Kinase Inhibitors or Docetaxel in Second-Line Treatment of EGFR Wild-Type Non-small-Cell Lung Cancer: A Retrospective Real-World Practice Review at a Single Tertiary Care Centre" Current Oncology 22, no. 3: 157-163. https://doi.org/10.3747/co.22.2296

APA Style

Ma, K., Cohen, V., Kasymjanova, G., Small, D., Novac, K., Peterson, J., Levit, A., & Agulnik, J. (2015). Kinase Inhibitors or Docetaxel in Second-Line Treatment of EGFR Wild-Type Non-small-Cell Lung Cancer: A Retrospective Real-World Practice Review at a Single Tertiary Care Centre. Current Oncology, 22(3), 157-163. https://doi.org/10.3747/co.22.2296

Article Metrics

Back to TopTop